251 related articles for article (PubMed ID: 9725779)
21. Association between nitric oxide and oxidative stress in continuous ambulatory peritoneal dialysis patients with peritonitis.
Duranay M; Yilmaz FM; Yilmaz G; Akay H; Parpucu H; Yücel D
Scand J Clin Lab Invest; 2007; 67(6):654-60. PubMed ID: 17852815
[TBL] [Abstract][Full Text] [Related]
22. Type I and III procollagens in CAPD: markers of peritoneal fibrosis.
Joffe P; Jensen LT
Adv Perit Dial; 1991; 7():158-60. PubMed ID: 1680415
[TBL] [Abstract][Full Text] [Related]
23. Encapsulating peritoneal sclerosis in patients undergoing continuous ambulatory peritoneal dialysis in Japan.
Nakamoto H; Kawaguchi Y; Suzuki H
Adv Perit Dial; 2002; 18():119-23. PubMed ID: 12402602
[TBL] [Abstract][Full Text] [Related]
24. Use of bolus intraperitoneal aminoglycosides for treating peritonitis in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis.
Mars RL; Moles K; Pope K; Hargrove P
Adv Perit Dial; 2000; 16():280-4. PubMed ID: 11045311
[TBL] [Abstract][Full Text] [Related]
25. Overview of regular dialysis treatment in Japan (as of 31 December 2005).
Nakai S; Masakane I; Akiba T; Iseki K; Watanabe Y; Itami N; Kimata N; Shigematsu T; Shinoda T; Syoji T; Syoji T; Suzuki K; Tsuchida K; Nakamoto H; Hamano T; Marubayashi S; Morita O; Morozumi K; Yamagata K; Yamashita A; Wakai K; Wada A; Tsubakihara Y
Ther Apher Dial; 2007 Dec; 11(6):411-41. PubMed ID: 18028170
[TBL] [Abstract][Full Text] [Related]
26. Lercanidipine-induced chyloperitoneum in patients on peritoneal dialysis.
Yang WS; Huang JW; Chen HW; Tsai TJ; Wu KD
Perit Dial Int; 2008; 28(6):632-6. PubMed ID: 18981394
[TBL] [Abstract][Full Text] [Related]
27. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
28. Tuberculous peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: case report and review.
Talwani R; Horvath JA
Clin Infect Dis; 2000 Jul; 31(1):70-5. PubMed ID: 10913399
[TBL] [Abstract][Full Text] [Related]
29. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
Akizuki O; Inayoshi A; Kitayama T; Yao K; Shirakura S; Sasaki K; Kusaka H; Matsubara M
Eur J Pharmacol; 2008 Apr; 584(2-3):424-34. PubMed ID: 18331727
[TBL] [Abstract][Full Text] [Related]
30. Comparative effects of carvedilol and lercanidipine on ultrafiltration and solute transport in CAPD patients.
Topal C; Erkoc R; Sayarlioglu H; Dogan E; Beyenik H
Ren Fail; 2009; 31(6):446-51. PubMed ID: 20187715
[TBL] [Abstract][Full Text] [Related]
31. Use of intraperitoneal urokinase for resistant bacterial peritonitis in continuous ambulatory peritoneal dialysis.
Tong MK; Leung KT; Siu YP; Lee KF; Lee HK; Yung CY; Kwan TH; Au TC
J Nephrol; 2005; 18(2):204-8. PubMed ID: 15931649
[TBL] [Abstract][Full Text] [Related]
32. Dihydropyridine calcium channel blockers: a rare and reversible cause of hepatotoxicity with cholestasis in a CAPD patient.
Basile C; Mascia E
Nephrol Dial Transplant; 1999 Nov; 14(11):2776-7. PubMed ID: 10534534
[No Abstract] [Full Text] [Related]
33. Lymphoma-mimicking peritonitis in a patient on continuous ambulatory peritoneal dialysis (CAPD).
Vlahakos D; Rudders R; Simon G; Canzanello VJ
Perit Dial Int; 1990; 10(2):165-7. PubMed ID: 2085602
[TBL] [Abstract][Full Text] [Related]
34. [A case of primary aldosteronism presenting hypokalemic myopathy induced by benidipine hydrochloride; a dihydropyridine calcium channel blocker].
Sugawara H; Shiraiwa H; Otsuka M; Ueki A
Rinsho Shinkeigaku; 2000 May; 40(5):446-51. PubMed ID: 11002726
[TBL] [Abstract][Full Text] [Related]
35. Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis.
Montenegro J; Saracho R; Gallardo I; Martínez I; Muñoz R; Quintanilla N
Nephrol Dial Transplant; 2007 Jun; 22(6):1703-8. PubMed ID: 17405794
[TBL] [Abstract][Full Text] [Related]
36. Incidence and clinical course of lercanidipine-associated cloudy effluent in continuous ambulatory peritoneal dialysis.
Hsiao PJ; Lin HW; Sung CC; Wang CW; Chu P; Lin SH
Clin Nephrol; 2010 Sep; 74(3):217-22. PubMed ID: 20860906
[TBL] [Abstract][Full Text] [Related]
37. Lercanidipine-induced chylous ascites: Case report and literature review.
Basualdo JE; Rosado IA; Morales MI; Fernández-Ros N; Huerta A; Alegre F; Landecho MF; Lucena JF
J Clin Pharm Ther; 2017 Oct; 42(5):638-641. PubMed ID: 28485829
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of cefdinir and its transfer to dialysate in patients with chronic renal failure undergoing continuous ambulatory peritoneal dialysis.
Tomino Y; Fukui M; Hamada C; Inoue S; Osada S
Arzneimittelforschung; 1998 Aug; 48(8):862-7. PubMed ID: 9748717
[TBL] [Abstract][Full Text] [Related]
39. The newly developed calcium antagonist, azelnidipine, increases drain volume in continuous ambulatory peritoneal dialysis patients.
Suzuki H; Inoue T; Kobayashi K; Shoda J; Nakamoto H
Adv Perit Dial; 2006; 22():18-23. PubMed ID: 16983932
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the direct negative dromotropic effect of a new calcium channel blocker, cilnidipine, with that of nicardipine.
Sugiyama A; Satoh Y; Takahara A; Ando K; Nakamura Y; Hashimoto K
Heart Vessels; 2005 May; 20(3):112-5. PubMed ID: 15912307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
